PMID- 15678915
OWN - NLM
STAT- MEDLINE
DCOM- 20050422
LR  - 20071115
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 45
IP  - 12
DP  - 2004 Dec
TI  - [Prognostic efficacy for measurement of real-time quantitative PCR-based major 
      bcr/abl mRNA in patients with Philadelphia chromosome-positive leukemia].
PG  - 1241-6
AB  - Evaluation of minimal residual disease (MRD) provides prognostic information on 
      various hematological malignancies. We describe here the prognostic efficacy of 
      real-time quantitative polymerase chain reaction (RQ-PCR)-based analysis of major 
      bcr/abl mRNA in cases of Philadelphia chromosome-positive leukemia (Ph-leukemia). 
      Twenty-one patients with Ph-leukemia were enrolled as subjects to determine the 
      usefulness of RQ-PCR-based measurement of bcr-abl/abl ratios. Imatinib mesylate 
      (imatinib) was administered to seven of the 21 patients before allogeneic stem 
      cell transplantation (SCT). Hematological relapse or failure of treatment with 
      SCT was observed in 2 of those patients who showed bcr-abl/abl ratios of more 
      than 0.002%, and 5 of the 7 patients showed both RQ-PCR and RT-PCR negativity 
      immediately after SCT. All of the 5 patients who did not receive imatinib before 
      allogeneic SCT showed RQ-PCR negativity immediately after SCT, but the results of 
      RT-PCR were positive in 3 patients at the same time points, and those became 
      negative after donor lymphocyte infusion or the appearance of graft-versus-host 
      disease. Administration of imatinib before SCT was thought to induce an early 
      remission. On the other hand, 8 patients who received imatinib without SCT showed 
      a remarkable decrease in bcr-abl/abl ratios. The ratio gradually rose in one 
      patient with Ph+ALL, enabling prediction of the hematological relapse preceding 
      detection by fluorescence in situ hybridization (FISH) analysis. Standardization 
      of RQ-PCR analysis of bcr-abl mRNA will help to predict early hematological 
      relapse in patients with MRD. In conclusion, it is thought that measurement of 
      RQ-PCR-based major bcr/abl mRNA in patients who were given imatinib and were 
      treated with SCT is useful for the evaluation of MRD and in deciding additional 
      treatment.
FAU - Takahata, Mutsumi
AU  - Takahata M
AD  - Department of Gastroenterology and Hematology, Hokkaido University Graduate 
      School of Medicine.
FAU - Hashino, Satoshi
AU  - Hashino S
FAU - Fujisawa, Fumie
AU  - Fujisawa F
FAU - Kondo, Takeshi
AU  - Kondo T
FAU - Ota, Syuichi
AU  - Ota S
FAU - Kobayashi, Sumiko
AU  - Kobayashi S
FAU - Tanaka, Junji
AU  - Tanaka J
FAU - Imamura, Masahiro
AU  - Imamura M
FAU - Asaka, Masahiro
AU  - Asaka M
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Adult
MH  - Female
MH  - Genes, abl/*genetics
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics/*mortality
MH  - Male
MH  - Middle Aged
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - RNA, Messenger/analysis
EDAT- 2005/02/01 09:00
MHDA- 2005/04/23 09:00
CRDT- 2005/02/01 09:00
PHST- 2005/02/01 09:00 [pubmed]
PHST- 2005/04/23 09:00 [medline]
PHST- 2005/02/01 09:00 [entrez]
PST - ppublish
SO  - Rinsho Ketsueki. 2004 Dec;45(12):1241-6.